Moderna, Merck’s experimental cancer vaccine cuts melanoma recurrence risk by 42%: Report
Moderna and Merck's experimental cancer vaccine, intismeran, reduced melanoma recurrence risk by 42% when combined with standard treatment post-surgery, according to a study released on Thursday. This personalized vaccine, based on mRNA technology, represents a significant advancement in cancer treatment. Further research is ongoing for similar vaccines targeting other cancers.